Despite living in a world mainly dominated by COVID-19, here at CleanAir by Baker, we feel that it is still important to support those working in patient and clinical care throughout the world.
As vaccines are rolled out in many countries and immunization programmes commence, the hope for a new normality could soon be on the horizon.
At CleanAir by Baker, we have been #SupportingScience since 1969 and with new vaccines and therapeutics worldwide, we will continue to do so now more than ever!
Swissmedic, the Swiss Agency for Therapeutic products authorized Moderna’s COVID-19 vaccine for adults, aged 18+.
The vaccine is the second COVID-19 vaccine to be authorized in Switzerland following that of Pfizer and BioNTech back in December.
The initial delivery of 200,000 doses will be made to the Armed Forces Pharmacy, which will distribute the vaccine to Switzerland’s cantons. With a total of 7.5 million doses lined up, this represents the country’s largest COVID-19 vaccine order.
Under the national vaccination strategy, priority is being given to the most vulnerable first.
Research has shown that the Pfizer and BioNTech vaccine can still target a key mutation that has emerged in two new variants of Coronavirus.
The results of the study show that the immune systems of vaccinated patients were able to take out the mutation, however the variant that has now emerged contains multiple mutations, whose combined effects may help the virus to evade the immune system entirely.
AstraZeneca and Oxford University applied for authorization for their COVID-19 vaccine in the EU. Studies have suggested that the vaccine is less effective than two vaccines already approved, however, is also cheaper and easier to make.
Providing the data submitted on the quality, safety and efficacy of the vaccine are sufficient, the EU will work as quickly as possible to authorize its use in Europe
Last week, the first vaccines were administered in Noord-Brabant, Rotterdam and Utrecht to healthcare workers, as The Netherlands rolls out its immunization programme.
Red cross volunteers have been recruited to help at vaccination facilities, and by the end of the week, all 25 health board regions will have started immunizing staff in hospitals and healthcare facilities.
Last month, NIAID announced the commencement of the Phase III trial of the Novavax investigational COVID-19 vaccine, NVX-Co-V2373.
The trial will look to evaluate the effectiveness of the vaccine along with its immune response and safety.
Involving 30,000 volunteers, the trial is funded, randomized and placebo-controlled by NIH and BARDA.
Make sure you join us in #SupportingScience across all of our social media channels!
Follow us on Facebook, Twitter, LinkedIn and Instagram.
1. https://www.biopharma-reporter.com/Article/2021/01/12/Swissmedic-gives-Moderna-COVID-19-vaccine-the-green-light, 2. https://www.bbc.co.uk/news/health-55587320,
3. https://www.dw.com/en/coronavirus-astrazeneca-applies-for-eu-approval-of-its-vaccine/a-56200665, 4. https://www.dutchnews.nl/news/2021/01/vaccination-of-healthcare-workers-begins-in-three-more-regions/,
Back to News
Because of Covid-19, our office staff of course also works at home. It might be that at some moments we are a bit less reachable by phone than you are used to from us. Please send us an e-mail: